MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up – What’s Next?

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) gapped up prior to trading on Thursday . The stock had previously closed at $11.29, but opened at $16.19. MoonLake Immunotherapeutics shares last traded at $14.52, with a volume of 16,975,598 shares trading hands.

Key Stories Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: FDA feedback may allow a skin drug filing for SLK without new clinical trials, reducing regulatory risk and supporting a faster BLA path. MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
• Positive Sentiment: HC Wainwright reaffirmed a Buy and raised its price target to $32, signaling stronger analyst conviction and giving investors a higher upside benchmark. Benzinga: HC Wainwright rating/price target
• Positive Sentiment: Needham maintained a Buy rating and $20 target, citing regulatory de‑risking on HS and 2026 inflammatory disease catalysts as supporting the investment case. MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
• Positive Sentiment: Retail momentum and speculation about potential M&A conversations amplified the rally, attracting heavy trading volume and short‑term buying interest. MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations
• Neutral Sentiment: Analysts and commentators view the FDA Type B meeting as momentum ahead of a planned BLA submission; this is positive if regulators agree but not a guarantee of approval. MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
• Neutral Sentiment: Explanatory pieces trace the pre‑market surge and investor interest — useful for context but not new catalyst information. Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 34.28%
• Negative Sentiment: Fundamentals remain loss‑making (recent EPS misses and negative forecasted EPS), and regulatory outcomes or labeling negotiations could still require additional data or post‑market commitments. Investors should weigh binary regulatory risk and past volatility. MarketBeat MLTX profile (financials & recent results)

Wall Street Analyst Weigh In

MLTX has been the subject of a number of analyst reports. The Goldman Sachs Group restated a “neutral” rating and set a $7.00 price objective on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 1st. UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $32.00 price target (up previously from $26.00) on shares of MoonLake Immunotherapeutics in a report on Friday. Wedbush dropped their price objective on MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 30th. Finally, Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $25.54.

MoonLake Immunotherapeutics Trading Up 28.9%

The company has a debt-to-equity ratio of 0.25, a current ratio of 8.50 and a quick ratio of 8.50. The business’s 50-day moving average is $13.18 and its two-hundred day moving average is $31.56. The firm has a market cap of $1.19 billion, a P/E ratio of -5.57 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period in the prior year, the business posted ($0.56) EPS. As a group, analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, insider Kristian Reich sold 130,000 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the insider directly owned 72,908 shares in the company, valued at approximately $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the sale, the chief executive officer directly owned 2,948,577 shares in the company, valued at $44,464,541.16. This trade represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 402,908 shares of company stock valued at $5,987,162 over the last three months. 12.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new stake in MoonLake Immunotherapeutics during the 3rd quarter worth approximately $28,000. Bank of America Corp DE increased its position in MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after buying an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after buying an additional 3,166 shares during the period. Covestor Ltd acquired a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $46,000. Finally, BNP Paribas Financial Markets boosted its position in shares of MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after acquiring an additional 1,158 shares during the period. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.